Immunome IMNM Stock
Immunome Price Chart
Immunome IMNM Financial and Trading Overview
| Immunome stock price | 19.81 USD |
| Previous Close | 21.83 USD |
| Open | 21.25 USD |
| Bid | 15.28 USD x 200 |
| Ask | 25.84 USD x 200 |
| Day's Range | 20.1 - 21.69 USD |
| 52 Week Range | 7.96 - 27.65 USD |
| Volume | 1.49M USD |
| Avg. Volume | 1.19M USD |
| Market Cap | 2.35B USD |
| Beta (5Y Monthly) | 2.115 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.39 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 35.36 USD |
IMNM Valuation Measures
| Enterprise Value | 1.89B USD |
| Trailing P/E | N/A |
| Forward P/E | -10.028571 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 586.1378 |
| Price/Book (mrq) | 3.9946175 |
| Enterprise Value/Revenue | 471.546 |
| Enterprise Value/EBITDA | -8.364 |
Trading Information
Immunome Stock Price History
| Beta (5Y Monthly) | 2.115 |
| 52-Week Change | 140.94% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 27.65 USD |
| 52 Week Low | 7.96 USD |
| 50-Day Moving Average | 22.14 USD |
| 200-Day Moving Average | 18.72 USD |
IMNM Share Statistics
| Avg. Volume (3 month) | 1.19M USD |
| Avg. Daily Volume (10-Days) | 1.22M USD |
| Shares Outstanding | 113.25M |
| Float | 108.33M |
| Short Ratio | 20.68 |
| % Held by Insiders | 6.30% |
| % Held by Institutions | 108.32% |
| Shares Short | 17.63M |
| Short % of Float | 18.21% |
| Short % of Shares Outstanding | 15.57% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -5698.82% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -29.71% |
| Return on Equity (ttm) | -50.14% |
Income Statement
| Revenue (ttm) | 4.02M USD |
| Revenue Per Share (ttm) | 0.04 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -182780000 USD |
| EBITDA | -226350000 USD |
| Net Income Avi to Common (ttm) | -224592992 USD |
| Diluted EPS (ttm) | -2.39 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 582.69M USD |
| Total Cash Per Share (mrq) | 5.15 USD |
| Total Debt (mrq) | 3.69M USD |
| Total Debt/Equity (mrq) | 0.63 USD |
| Current Ratio (mrq) | 21.681 |
| Book Value Per Share (mrq) | 5.202 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -196502000 USD |
| Levered Free Cash Flow (ttm) | -139312992 USD |
Profile of Immunome
| Country | United States |
| State | WA |
| City | Bothell |
| Address | 18702 North Creek Parkway |
| ZIP | 98011 |
| Phone | 425 939 7410 |
| Website | https://immunome.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 206 |
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Q&A For Immunome Stock
What is a current IMNM stock price?
Immunome IMNM stock price today per share is 19.81 USD.
How to purchase Immunome stock?
You can buy IMNM shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Immunome?
The stock symbol or ticker of Immunome is IMNM.
Which industry does the Immunome company belong to?
The Immunome industry is Biotechnology.
How many shares does Immunome have in circulation?
The max supply of Immunome shares is 113.25M.
What is Immunome Price to Earnings Ratio (PE Ratio)?
Immunome PE Ratio is now.
What was Immunome earnings per share over the trailing 12 months (TTM)?
Immunome EPS is -2.39 USD over the trailing 12 months.
Which sector does the Immunome company belong to?
The Immunome sector is Healthcare.
Immunome IMNM included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
- {{ link.label }} {{link}}